All In Biotech

Drug Trial Radar · NCT04001517

Cognitive Effects of Oral p38 Alpha Kinase Inhibitor Neflamapimod in Dementia With Lewy Bodies

A Double-Blind, Placebo-Controlled 16-Week Study of the Cognitive Effects of Oral p38 Alpha Kinase Inhibitor Neflamapimod in Dementia With Lewy Bodies (DLB)

Last checked: Nov 19, 2026Latest source record: Jun 29, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

91

Actual

Start

Sep 30, 2019

Primary completion

Jun 30, 2020

Study completion Jun 30, 2020

Sponsor

Lead sponsor
EIP Pharma IncIndustry
Sponsor type
Industry
Collaborators
Worldwide Clinical Trials
First posted
Jun 28, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2, multi-center, randomized, double-blind, placebo-controlled, proof-of-principle study of neflamapimod versus matching placebo (randomized 1:1) administered with food for 16 weeks in subjects with DLB. The primary objective is to evaluate the effect of neflamapimod on cognitive function as assessed in a study-specific Cogstate Neuropsychological Test Battery (NTB). Secondary endpoints include the Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB), Mini-Mental State Examination (MMSE), Neuropsychiatric Inventory (NPI-10), Timed Up and Go Test, and electroencephalogram (EEG) as a potential biomarker for DLB.

Conditions

  • Dementia With Lewy Bodies (DLB)

Interventions

  • NeflamapimodDrug

    Double-Blind, Placebo-Controlled

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Composite Z-score of a Study-specific Neuropsychological Test Battery (NTB) Including Tests From Cogstate Battery, Letter Fluency Test and Category Fluency TestTime frame: As the analysis was by Mixed Model for Repeated Measures, all time points at which NTB was assessed utilized in the analysis. The difference reported is the mean difference over the entire course of the study.

Locations

24 sites in 2 countries. Site status is shown where the registry gives one.

  • University of California San Diego (UCSD)

    La Jolla, California

  • Pacific Neuroscience Institute

    Santa Monica, California

  • University of Colorado

    Aurora, Colorado

  • Elite Clinical Research

    Miami, Florida

  • University of Kansas Medical Center

    Kansas City, Kansas

  • Massachusetts General Hospital

    Charlestown, Massachusetts

  • University of Michigan

    Ann Arbor, Michigan

  • Mayo Clinic

    Rochester, Minnesota

  • Cleveland Clinic - Lou Ruvo Center for Brain Health

    Las Vegas, Nevada

  • New York Presbyterian Hospital - Columbia University Medical Center

    New York, New York

  • University of Rochester

    Rochester, New York

  • University of North Carolina

    Chapel Hill, North Carolina

  • Cleveland Clinic

    Cleveland, Ohio

  • The Ohio State University

    Columbus, Ohio

  • Summit Research Network

    Portland, Oregon

  • Oregon Health & Science University

    Portland, Oregon

  • Thomas Jefferson University

    Philadelphia, Pennsylvania

  • University of Virginia

    Charlottesville, Virginia

  • National Clinical Research, Inc.

    Richmond, Virginia

  • Northwest Clinical Research Center

    Bellevue, Washington

  • University of Washington

    Seattle, Washington

  • Inland Northwest Research

    Spokane, Washington

  • Brain Research Center

    's-Hertogenbosch, Netherlands

  • Brain Research Center

    Amsterdam, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.